The size of the Haemostatic Agents Market in the Asia Pacific is forecasted to increase at a promising CAGR from 2021 to 2026.
Haemostatic Agents refers to the class of substances that are usually used to promote haemostasis or to stop bleeding. Haemostats are the technical term given to instruments used to reduce or halt bleeding during a surgical procedure.
The major technological advancements in the field have increased the usage of haemostats in surgical procedures in recent times. Common problems faced by haemostats include tissue contamination and ease of usage. These have been addressed in the latest wave of innovations
The major factors affecting the Haemostatic Agents market include the rising prevalence of diseases and rising awareness regarding latest medical practices. Other drivers include increasing health consciousness among consumers, use of new inventions and enhanced technologies. As for the restraints of the market, the high costs and the unfavourable reimbursement policies are the major hurdles. This along with the fact that people are not aware of the latest developments in developing and underdeveloped countries restrain the market growth.
This research report on the Asia Pacific Haemostatic Agents Market has been segmented and sub-segmented into the following categories:
Regionally, Asia-Pacific is expected to grow rapidly in the coming years as is evident from the high CAGR value for the region. In addition to having the highest growth rate, the region also has the third highest market share. The rapid growth of the region can be attributed to the developing stature of countries such as India and China.
Companies dominating the Asia Pacific Haemostatic Agents Market profiled in this report are Ethicon, Pfizer, Baxter International, R. Bard, The Medicines Company, Anika Therapeutics, Advanced Medical Solutions, Integra LifeSciences, B Braun Melsungen, Gelita Medical, Equimedical, Vascular Solutions, Marine Polymer Technologies and Z-Medica.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Thrombin Based Haemostats
5.1.3 Gelatin Based Haemostats
5.1.4 Collagen Based Haemostats
5.1.5 Oxidized Regenerated Cellulose Based Haemostats
5.1.6 Combination Haemostats
5.1.7 Fibrin Sealants
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Type
5.1.10 Market Attractiveness Analysis, By Type
5.1.11 Market Share Analysis, By Type
5.2 Treatment
5.2.1 Introduction
5.2.2 Cardiovascular
5.2.3 General Surgery
5.2.4 Digestive Surgery
5.2.5 Neurosurgery
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Treatment
5.2.8 Market Attractiveness Analysis, By Treatment
5.2.9 Market Share Analysis, By Treatment
5.3 End User
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Surgery Centres
5.3.4 Nursing Homes
5.3.5 Others
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Treatment
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Treatment
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Treatment
6.1.5.4 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Ethicon
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer
8.3 Baxter International
8.4 R. Bard
8.5 The Medicines Company
8.6 Anika Therapeutics
8.7 Advanced Medical Solutions
8.8 Integra Life Sciences
8.9 Gelita Medical
8.10 Z-Medica
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
